Stay updated on ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial

Sign up to get notified when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value (Estimated) has recently changed to . This change likely indicates an update in the estimated primary completion date for a Phase 1/2 clinical trial evaluating the safety and efficacy of ARV-471 alone and in combination with palbociclib in patients with ER+/HER2- breast cancer.
    Difference
    0.1%
    Check dated 2024-05-07T20:07:21.000Z thumbnail image
  7. Check
    12 days ago
    Change Detected
    Summary
    The clinical trial site in Knoxville, Tennessee, United States, with the study contact name Arvinas Estrogen Receptor, Inc., has transitioned from being withdrawn to active, not recruiting. The change indicates that the site is now actively participating in the study after previously being withdrawn.
    Difference
    4%
    Check dated 2024-05-06T17:53:22.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:47:34.000Z thumbnail image

Stay in the know with updates to ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.